To report a possible interaction between warfarin and ceftaroline, resulting in hemarthrosis, and provide readers with an understanding of mechanisms of interaction between cephalosporins and warfarin.
CASE SUMMARY:
Ceftaroline was prescribed for an 85-year-old female with a therapeutic international normalized ratio (INR) hospitalized for the treatment of cellulitis. She was subsequently readmitted with shoulder pain and a supratherapeutic INR. The patient was diagnosed with hemarthrosis, presumably related to elevated INR. Evaluation using the drug interaction probability scale for warfarin and ceftaroline yielded a score consistent with a possible or probable interaction.
DISCUSSION:
Cephalosporins may interact with warfarin through a variety of mechanisms, including potentiation of hypoprothrombinemia related to certain side chain groups, inhibition of P-glycoprotein, or alteration of gastrointestinal flora. All mechanisms reported in the medical literature as of April 2012 are briefly examined, but the latter is the most reasonable mechanism for a ceftaroline interaction with warfarin.
CONCLUSIONS:
Health care providers should consider closely monitoring patients receiving antibiotics with activity against Enterobacteriaceae and warfarin, even if no direct mechanism of interaction has been reported. Further research regarding a ceftaroline-warfarin interaction is warranted.
WallinR, SaneDC, HutsonSM. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res2002; 108: 221–6. DOI: 10.1016/S0049-3848(03)00060-4
2.
LeeA, CrowtherM. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis2011; 31: 249–58. DOI: 10.1007/s11239-011-0555-z
3.
AnsellJ, HirshJ, HylekE, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest2008; 133: 160–98. DOI: 10.1378/chest.08-0670
4.
HornJR, HanstenPD, ChanLN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother2007; 41: 674–80. DOI: 10.1345/aph.1H423
5.
ConlyJ, SteinK. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med1994; 17: 531–9.
6.
UdallJA. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA1965; 194: 107–9.
7.
DavydovL, YermolnikM, CuniLJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother2003; 37: 367–70. DOI: 10.1345/aph.1C243
8.
ZhangQ, SimoneauG, VerstuyftC, et al. Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial. Br J Clin Pharmacol2011; 71: 232–6. DOI: 10.1111/j.1365-2125.2010.03824.x
9.
PanagiotidisG, BäckströmT, Asker-HagelbergC, JandourekA, WeintraubA, NordCE. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother2010; 54: 1811. DOI: 10.1128/AAC.01716-09
10.
SaravolatzLD, SteinGE, JohnsonLB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis2011; 52: 1156–63. DOI: 10.1093/cid/cir147
11.
StromBL, SchinnarR, GibsonGA, BrennanPJ, BerlinJA. Risk of bleeding and hypoprothrombinemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf1999; 8: 81–94.
12.
AgnelliG, FaveroAD, PariseP, et al. Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit?Antimicrob Agents Chemother1986; 29: 1108–9.
13.
WelageLS, BorinMT, WiltonJH, et al. Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole. Antimicrob Agents Chemother1990; 34: 2369–74.
14.
KerremansAL, LipskyJL, Van LoonJ, GallegoMO, WeinshilboumRM. Cephalosporin-induced hypoprothrombinemia: possible role for thiol methylation of 1-methyltetrazole-5-thiol and 2-methyl-1,3,4-thiadiazole-5-thiol. J Pharmacol Exp Ther1985; 235: 382–8.
15.
Package insert. Teflaro (ceftaroline fosamil). St. Louis, MO: Forest Laboratories, Inc., February 2011.
16.
BartlettJG. Antibiotic-associated diarrhea. N Engl J Med2002; 346: 334–9.
17.
HylekEM, HeimanH, SkatesSJ, SheehanMA, SingerDE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA1998; 279: 657–62.
18.
SmithJK, AljazairiA, FullerSH. INR elevation associated with diarrhea in a patient receiving warfarin. Ann Pharmacother1999; 33: 301–4. DOI: 10.1345/aph.18171
19.
Custódio das DôresSM, BoothSL, MartiniLA, et al. Relationship between diet and anticoagulant response to warfarin: a factor analysis. Eur J Nutr2007; 46: 147–54. DOI: 10.1007/s00394-007-0645-z
20.
CourisR, TataronisG, McCloskeyW, et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res2006; 76: 65–74.
21.
LurieY, LoebsteinR, KurnikD, AlmogS, HalkinH. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol2010; 70: 164–70. DOI: 10.1111/j.1365-2125.2010.03672.x
22.
TanigawaraY. Role of P-glycoprotein in drug disposition. Ther Drug Monit2000; 22: 137–40.
23.
WadeliusM, SorlinK, WallermanO, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J2004; 4: 40–8. DOI: 10.1038/sj.tpj.6500220
24.
GoslandMP, LumBL, SikicBI. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res1989; 49: 6901–5.
25.
RettieAE, KorzekwaKR, KunzeKL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin–drug interactions. Chem Res Toxicol1992; 5: 54–9. DOI: 10.1021/tx00025a009
26.
LaneS, Al-ZubiediS, HatchE, et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol2012; 73: 66–76. DOI: 10.1111/j.1365-2125.2011.04051.x
27.
NutescuE, ChuatrisornI, HellenbartE. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis2011; 31: 326–43. DOI: 10.1007/s11239-011-0561-1
28.
ToutainPL, Bousquest-MelouA. Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther2002; 25: 460–3. DOI: 10.1046/j.1365-2885.2002.00442.x
29.
RolanPE. Plasma protein binding displacement interactions—why are they still regarded as clinically important?Br J Clin Pharmac1994; 37: 125–8.
30.
UdenP, SvedbergLE, NordgrenA, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol1992; 34: 509–12.
31.
TargownikLE, BoltonJM, MetgeCJ, LeungS, SareenJ. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol2009; 104: 1475–82. DOI: 10.1038/ajg.2009.128
32.
TullyPJ, CardinalT, BennettsJS, BakerRA. Selective serotonin reuptake inhibitors, venlafaxine and duloxetine are associated with in hospital morbidity but not bleeding or late mortality after coronary artery bypass graft Surgery. Heart Lung Circ2012; 21: 206–14. DOI: 10.1016/j.hlc.2011.12.002
YavasogluI, KadikoyluG, BolamanZ. Gingival bleeding due to venlafaxine. Ann Pharmacother2008; 42: 144–5. DOI: 10.1345/aph.1K180
35.
HansenML, SorensenR, ClausenMT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med2010; 170: 1433–41. DOI: 10.1001/archinternmed.2010.271
36.
LipGYH, FrisonL, HalperinJL, LaneDA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol2011; 57: 173–80. DOI: 10.1016/j.jacc.2010.09.024
37.
DentaliF, DouketisJD, LimW, CrowtherM. Combined aspirin–oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med2007; 167: 117–24.
38.
HurlenM, AbdelnoorM, SmithP, ErikssenJ, ArnesenH. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med2002; 347: 969–74.
39.
GilleJ, BernotatJ, BöhmS, BehrensP, LöhrJF. Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. Z Rheumatol2003; 62: 80–1. DOI: 10.1007/s00393-003-0420-3
40.
SconceEA, KhanTI, DalyAK, WynneHA, KamaliF. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost2006; 4: 1422–4.
Muntane-RelatJ, OurlinJC, DomergueJ, MaurelP. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology1995; 22 (4 pt 1): 1143–53.
